亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯(lián)系方式|購物車
企業(yè)會員第1年

成都鈉鈳鋰生物科技有限公司  

自制標準品對照品,各類植物提取物

搜索
新聞中心
  • 暫無新聞
產(chǎn)品分類
  • 暫無分類
聯(lián)系方式
  • 聯(lián)系人:李曼
  • 電話:028-61983833
  • 郵件:cdnakeli@163.com
  • 微信:18000507060
  • QQ:1373789011
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產(chǎn)品 > 巴利森苷E CAS:952068-57-4
巴利森苷E CAS:952068-57-4
單價 面議對比
詢價 暫無
發(fā)貨 四川成都市付款后3天內
品牌 鈉鈳鋰
過期 長期有效
更新 2021-11-25 12:22
 
詳細信息

nkl-00219
中文名稱:巴利森苷E
中文別稱:派立辛 E;檸檬酸酯E
英文名稱:Parishin E
英文別稱:4-[(3,4-Dicarboxy-3-hydroxy-1-oxobutoxy)methyl]phenyl β-D-glucopyranoside; Parishin E
C A S號:952068-57-4
度:HPLC≥98%

式:C19H24O13
量:460.39
沸點: 784.1±60.0 °C | Condition
密度: 1.631±0.06 g/cm3 | Condition: Temp: 20 °C
: 3.10±0.28 | Condition: Most Acidic Temp: 25 °C
規(guī)格:20mg  50mg  100mg  500mg  g級等應客戶需求包裝
儲存條件: 2-8°C,避光、干燥、密封

用途: 用于鑒別、含量測定、藥理實驗、活性篩選等科研、實驗室使用;不得用于注射、食用或其他

供應商:成都鈉鈳鋰生物科技有限公司

©2025 成都鈉鈳鋰生物科技有限公司 版權所有   技術支持:化工網(wǎng)   訪問量:21476  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |